🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being viewed as a "huge turning point" in the effort against increasingly resistant strains of the bacteria, according to scientists.

A Global Public Health Issue

Cases of gonorrhoea are escalating worldwide, with figures suggesting in excess of 82 million infections per year. Particularly high rates are reported in the African continent and countries within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune development in the context of increasing worldwide cases, escalating drug resistance and the extremely scarce treatment choices at this time.”

Health officials are particularly alarmed about the increase in treatment-resistant strains. The WHO has listed it as a "priority pathogen". A tracking program revealed that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Therapies Gain Authorization

Zoliflodacin, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in recent days for use against gonorrhoea. This STI can lead to significant complications, including infertility. Scientists believe that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, originating from the drugmaker GSK, was also approved in close succession. This medication, which is additionally indicated for urinary tract infections, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin was the result of a innovative non-profit model for drug creation. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to develop it.

“This milestone signifies a significant shift in the management of superbug gonorrhoea, which until now has been staying ahead of antibiotic development.”

Testing Data and Global Access

Based on findings published in a major medical journal, the new drug successfully treated over nine in ten of uncomplicated infections. This establishes an similar efficacy with the typical regimen, which uses a dual-drug approach. The study enrolled hundreds of patients from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, GARDP has the ability to register and commercialise the drug in a wide range of low-income and middle-income countries.

Medical professionals directly involved have expressed hope. Having a single-dose, oral treatment such as this is hailed as a "game-changer" for gonorrhoea control. This is deemed essential to alleviate the strain of the disease for individuals and to prevent the spread of untreatable gonorrhoea globally.